REGENXBIO, co-founded by James Wilson, MD, PhD, Emeritus Professor of Medicine at Penn Medicine, reported new data demonstrating durable, long-term functional improvement at 18 months in Duchenne Muscular Dystrophy patients treated with a pivotal dose. Read more here.